Loading...
  • adjuvant treatment
  • The cumulative risk of developing treatment-related AML or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who received adjuvant treatment with epirubicin-containing regimens, was estimated as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years. (nih.gov)
  • occur
  • Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin or months to years after termination of therapy. (nih.gov)
  • Cardiac toxicity with epirubicin may occur at lower cumulative doses whether or not cardiac risk factors are present. (nih.gov)
  • medicines
  • Epirubicin belongs to the group of medicines called antineoplastics. (drugs.com)
  • When you are receiving epirubicin, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. (drugs.com)
  • Using epirubicin with any of the following medicines is not recommended. (drugs.com)
  • treatment
  • While you are being treated with epirubicin, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctor's approval. (mayoclinic.org)
  • Worse side effects from radiation treatment have happened with epirubicin. (drugs.com)
  • leukemia
  • Secondary acute myelogenous leukemia (AML) has been reported in patients with breast cancer treated with anthracyclines, including epirubicin. (nih.gov)
  • lower
  • Epirubicin may lower your body's resistance, and there is a chance you might get the infection the immunization is meant to prevent. (mayoclinic.org)
  • Epirubicin can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. (mayoclinic.org)
  • activity
  • Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. (nih.gov)
  • Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. (drugbank.ca)